AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25802966 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface peroneal nerve stimulation
Number of subjects: 110
Study 25802966 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110
Study 23479592 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg lycopene/day
Number of subjects: 42
Study 23479592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 21130359 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture as an adjunct therapy
Number of subjects: 9
Study 21130359 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 9
Study 18230264 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoButton CL
Number of subjects: 56
Study 18230264 — intervention group
Group type: COMPARATOR
Intervention: Cross-pin fixation
Number of subjects: 56
Study 16802251 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE) performed 11 times per week
Number of subjects: 20
Study 16802251 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE)
Number of subjects: 20
Study 16802251 — intervention group
Group type: COMPARATOR
Intervention: Control (Ctrl) group (non-exercising)
Number of subjects: 20
Study 16802251 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RVE and Ctrl)
Number of subjects: 20
Study 14608833 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80 mg daily for 6 months
Number of subjects: 20
Study 12629084 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (SP) 40 g daily for 3 months
Number of subjects: 71
Study 12629084 — intervention group
Group type: COMPARATOR
Intervention: Milk-based protein (MBP) 40 g daily for 3 months
Number of subjects: 71
Study 12080805 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine supplementation (15 g daily)
Number of subjects: 0
Study 12080805 — intervention group
Group type: COMPARATOR
Intervention: Glycine supplementation (25 g daily)
Number of subjects: 0
Study 8649051 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA (all-trans retinoic acid) plus chemotherapy
Number of subjects: 0
Study 8649051 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 0
Study 1754467 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIgG 400 mg/kg b.w. on 5 consecutive alternate days and subsequently after 15 days and monthly thereafter for up to six months (group B)
Number of subjects: 30
Study 1754467 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA 5‐10/kg b.w. by mouth in two daily doses for a period between 6 and 18 months (group C)
Number of subjects: 30
Study 1754467 — intervention group
Group type: COMPARATOR
Intervention: Control group A
Number of subjects: 30
Study 1754467 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIgG and CyA (group B and C)
Number of subjects: 30
Study 6626436 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofensine 25 mg
Number of subjects: 8
Study 6626436 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofensine 50 mg
Number of subjects: 8
Study 6626436 — intervention group
Group type: EXPERIMENTAL
Intervention: desmethylimipramine (DMI) 50 mg
Number of subjects: 8
Study 6626436 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study 3921328 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone (two tablets)
Number of subjects: 0
Study 3921328 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two tablets)
Number of subjects: 0
Study 30893070 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid supplement
Number of subjects: 16
Study 30893070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30117795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Saver (CS)
Number of subjects: 95
Study 30117795 — intervention group
Group type: COMPARATOR
Intervention: No Cell Saver (NCS)
Number of subjects: 95
Study 26047963 — intervention group
Group type: EXPERIMENTAL
Intervention: High flavanol drink (494 mg)
Number of subjects: 18
Study 26047963 — intervention group
Group type: COMPARATOR
Intervention: Low flavanol drink (23 mg)
Number of subjects: 18
Study 24296869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (5 mg b.i.d.)
Number of subjects: 221
Study 24296869 — intervention group
Group type: COMPARATOR
Intervention: β-blockers (carvedilol 6.25 mg b.i.d. or bisoprolol 1.25 mg b.i.d.)
Number of subjects: 221
Study 21439002 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based program
Number of subjects: 88
Study 21439002 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional face-to-face program
Number of subjects: 88
Study 21439002 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 18313445 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 5996
Study 16579996 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin 10.8 mg administered 24 hours after UAE
Number of subjects: 26
Study 16579996 — intervention group
Group type: COMPARATOR
Intervention: Control group (no goserelin)
Number of subjects: 26
Study 12948416 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 5 microg/kg
Number of subjects: 45
Study 12948416 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 10 microg/kg
Number of subjects: 45
Study 12948416 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 20 microg/kg
Number of subjects: 45
Study 10869739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Number of subjects: 232
Study 10869739 — intervention group
Group type: COMPARATOR
Intervention: Conventional Three-Dimensional Conformal Radiation Therapy (3D-CRT)
Number of subjects: 232
Study 9203444 — intervention group
Group type: EXPERIMENTAL
Intervention: trIGT
Number of subjects: 87
Study 9203444 — intervention group
Group type: EXPERIMENTAL
Intervention: pIGT
Number of subjects: 87
Study 9203444 — intervention group
Group type: COMPARATOR
Intervention: N-IGT
Number of subjects: 87
Study 9203444 — intervention group
Group type: COMPARATOR
Intervention: IGT-D
Number of subjects: 87
Study 9203444 — intervention group
Group type: COMPARATOR
Intervention: IGT-IGT
Number of subjects: 87
Study 9203444 — intervention group
Group type: COMPARATOR
Intervention: N-N
Number of subjects: 87
Study 8174949 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful eradication of H pylori in 12 patients
Number of subjects: 34
Study 8174949 — intervention group
Group type: COMPARATOR
Intervention: Unsuccessful eradication of H pylori in 22 patients
Number of subjects: 34
Study 3780284 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg betahistine dihydrochloride
Number of subjects: 88
Study 3780284 — intervention group
Group type: COMPARATOR
Intervention: 15 mg cinnarizine
Number of subjects: 88
Study 3780284 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 88
Study 3780284 — intervention group
Group type: COMPARATOR
Intervention: Cinnarizine
Number of subjects: 88
Study 3780284 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine
Number of subjects: 88
Study 30088562 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-implant assisted helical uprighting spring (MIA)
Number of subjects: 20
Study 30088562 — intervention group
Group type: COMPARATOR
Intervention: Conventional helical uprighting spring (CA)
Number of subjects: 20
Study 30088562 — intervention group
Group type: EXPERIMENTAL
Intervention: MIA
Number of subjects: 20
Study 30088562 — intervention group
Group type: COMPARATOR
Intervention: CA
Number of subjects: 20
Study 27809874 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT plus 30 min of moderate-intensity treadmill walking in the morning (ONE)
Number of subjects: 30
Study 27809874 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT plus six hourly 5-min microbouts of moderate-intensity treadmill walking (MICRO)
Number of subjects: 30
Study 27809874 — intervention group
Group type: COMPARATOR
Intervention: 6 h of uninterrupted sitting (SIT)
Number of subjects: 30
Study 25037462 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 70
Study 25037462 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 70
Study 25037462 — intervention group
Group type: COMPARATOR
Intervention: Fibrin sealant and Manual compression
Number of subjects: 70
Study 22012170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 I.U.)
Number of subjects: 100
Study 22012170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 20847753 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic hydrophobic AcrySof SA60AT IOLs
Number of subjects: 41
Study 20847753 — intervention group
Group type: COMPARATOR
Intervention: Silicone Tecnis Z9000 IOLs
Number of subjects: 41
Study 18455082 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily for 7 years)
Number of subjects: 18882
Study 18455082 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 7 years)
Number of subjects: 18882
Study 16647439 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast medium administration during donor evaluation (coronary angiography or levography)
Number of subjects: 72
Study 16647439 — intervention group
Group type: COMPARATOR
Intervention: No contrast medium administration during donor evaluation
Number of subjects: 72
Study 14520725 — intervention group
Group type: EXPERIMENTAL
Intervention: RDS infants
Number of subjects: 16
Study 14520725 — intervention group
Group type: COMPARATOR
Intervention: Control infants
Number of subjects: 16
Study 14520725 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 10736119 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive heating blanket set to 42 degrees C (107.6 degrees F)
Number of subjects: 8
Study 10736119 — intervention group
Group type: COMPARATOR
Intervention: Reflective foil (passive insulation)
Number of subjects: 8
Study 9178844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.83 mg/ml, 6 ml)
Number of subjects: 10
Study 9178844 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 9178844 — intervention group
Group type: COMPARATOR
Intervention: Saline (injected 1 week after ketamine treatment)
Number of subjects: 10
Study 9178844 — intervention group
Group type: COMPARATOR
Intervention: Saline (injected 2 weeks after ketamine treatment)
Number of subjects: 10
Study 1389240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (CFX) 1.5 g at induction of anaesthesia and then CFX 750 mg b.i.d. for 4 days (Group A)
Number of subjects: 226
Study 1389240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (CFX) 1.5 g and metronidazole (MTR) 1.0 g at induction of anaesthesia, then CFX 750 mg b.i.d. and MTR 500 mg qds for 4 days (Group B)
Number of subjects: 226
Study 1389240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (CFX) 1.5 g and metronidazole (MTR) 1.0 g at induction of anaesthesia (Group C)
Number of subjects: 226
Study 1389240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (CFX) 1.5 g on induction of anaesthesia (Group D)
Number of subjects: 226
Study 1389240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (CFX) 1.5 g on induction of anaesthesia then CFX 750 mg bd for 2 days (Group E)
Number of subjects: 226
Study 3901631 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemosorption treatment (n=90)
Number of subjects: 140
Study 3901631 — intervention group
Group type: COMPARATOR
Intervention: No hemosorption treatment (n=50)
Number of subjects: 140
Study 31032654 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal splint packing (group A)
Number of subjects: 60
Study 31032654 — intervention group
Group type: EXPERIMENTAL
Intervention: Merocel packing (group B)
Number of subjects: 60
Study 31032654 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 patients)
Number of subjects: 60
Study 26164214 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care intervention
Number of subjects: 134
Study 26164214 — intervention group
Group type: COMPARATOR
Intervention: Usual care/attention control
Number of subjects: 134
Study 23680441 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A Supplementation (VAS)
Number of subjects: 1673
Study 21534705 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding trials of joint absence or joint presence of events
Number of subjects: 0
Study 21534705 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding trials where one event occurs in the absence of another
Number of subjects: 0
Study 18279877 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral intake (EOI) group - clear liquid drink given 2 hours after surgery
Number of subjects: 200
Study 18279877 — intervention group
Group type: COMPARATOR
Intervention: Delayed oral intake (DOI) group - clear liquid drink given 8 hours after surgery
Number of subjects: 200
Study 18279877 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral intake (EOI) group
Number of subjects: 200
Study 18279877 — intervention group
Group type: COMPARATOR
Intervention: Delayed oral intake (DOI) group
Number of subjects: 200
Study 17302256 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon plus ribavirin therapy
Number of subjects: 9
Study 12898010 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg B2036‐PEG
Number of subjects: 7
Study 12898010 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg B2036‐PEG
Number of subjects: 7
Study 11885185 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 800
Study 11885185 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA)-coated implants
Number of subjects: 800
Study 11885185 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers (including those who quit)
Number of subjects: 800
Study 8757209 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin, 3 mg twice daily
Number of subjects: 279
Study 8757209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 1393459 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed grafts
Number of subjects: 226
Study 1393459 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ grafts
Number of subjects: 226
Study 1393459 — intervention group
Group type: EXPERIMENTAL
Intervention: Small vein grafts (< 4 mm in diameter)
Number of subjects: 226
Study 1393459 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein grafts (≥ 4 mm in diameter)
Number of subjects: 226
Study 3903735 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition counseling after withdrawal from drugs
Number of subjects: 0
Study 3903735 — intervention group
Group type: COMPARATOR
Intervention: No dietary change after withdrawal from drugs (Group II)
Number of subjects: 0
Study 3903735 — intervention group
Group type: COMPARATOR
Intervention: Continued drug treatment (Group III)
Number of subjects: 0
Study 30851861 — intervention group
Group type: COMPARATOR
Intervention: Intervention
Number of subjects: 228
Study 28815329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir with Ribavirin
Number of subjects: 30
Study 26705350 — intervention group
Group type: EXPERIMENTAL
Intervention: SAX
Number of subjects: 220
Study 26705350 — intervention group
Group type: EXPERIMENTAL
Intervention: LAX
Number of subjects: 220
Study 26705350 — intervention group
Group type: EXPERIMENTAL
Intervention: OAX
Number of subjects: 220
Study 24065417 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-thickness skin grafts
Number of subjects: 100
Study 24065417 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (control)
Number of subjects: 100
Study 22749332 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral suctioning (COS) using a saliva ejector connected to 100mmHg of suction.
Number of subjects: 27
Study 22749332 — intervention group
Group type: COMPARATOR
Intervention: Control group with conventional endotracheal tube without COS.
Number of subjects: 27
Study 22749332 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral suctioning (COS) using a saliva ejector.
Number of subjects: 27
Study 20133408 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate suppository
Number of subjects: 0
Study 20133408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17222282 — intervention group
Group type: EXPERIMENTAL
Intervention: CRA plus voucher-based incentives set at a high monetary value ($1995/12 weeks)
Number of subjects: 100
Study 17222282 — intervention group
Group type: COMPARATOR
Intervention: CRA with vouchers set at a low monetary value ($499/12 weeks)
Number of subjects: 100
Study 17222282 — intervention group
Group type: EXPERIMENTAL
Intervention: High-value voucher condition
Number of subjects: 100
Study 17222282 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of abstinence achieved during treatment
Number of subjects: 100
Study 15077095 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine supplementation
Number of subjects: 60
Study 15077095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12068339 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg bid
Number of subjects: 408
Study 12068339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study 9654222 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 cm/6 cm electrode length combination
Number of subjects: 15
Study 9654222 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 cm electrode in the right atrium
Number of subjects: 15
Study 9654222 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 cm electrode in the coronary sinus
Number of subjects: 15
Study 9247454 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IL-10 (0.5, 1, 5, 10, or 25 micrograms/kg) administered once daily by intravenous bolus injection over 7 consecutive days
Number of subjects: 46
Study 9247454 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered once daily by intravenous bolus injection over 7 consecutive days
Number of subjects: 46
Study 1657680 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucolytic-antifoam solution (simethicone, acetylcysteine, sodium bicarbonate)
Number of subjects: 43
Study 1657680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 6452806 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine 200 mg (single daily dose)
Number of subjects: 0
Study 6452806 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine 100 mg (divided dose)
Number of subjects: 0
Study 6452806 — intervention group
Group type: COMPARATOR
Intervention: Zimelidine (control group not specified)
Number of subjects: 0
Study 31697010 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser plus topical tioconazole 28% for five sessions with 3 weeks interval
Number of subjects: 120
Study 31697010 — intervention group
Group type: COMPARATOR
Intervention: Fractional CO2 laser for five sessions with 3 weeks interval
Number of subjects: 120
Study 31697010 — intervention group
Group type: COMPARATOR
Intervention: Topical tioconazole 28% for 16 weeks
Number of subjects: 120
Study 30776777 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 32
Study 30776777 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 32
Study 30776777 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 32
Study 29256407 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium lactate (360 mg elemental magnesium)
Number of subjects: 36
Study 29256407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 23648350 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-umbilicus laparoendoscopic one-trocar surgery
Number of subjects: 78
Study 23648350 — intervention group
Group type: COMPARATOR
Intervention: Trans-umbilicus and abdominal wall two-trocar laparoscopic surgery
Number of subjects: 78
Study 20863419 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis BB-12 (BB-12) administered twice a day (daily dose of 10 billion colony-forming units) from 1-2 months to 8 months.
Number of subjects: 109
Study 20863419 — intervention group
Group type: COMPARATOR
Intervention: Control tablet administered twice a day.
Number of subjects: 109
Study 19529055 — intervention group
Group type: EXPERIMENTAL
Intervention: Education sessions with husbands
Number of subjects: 442
Study 19529055 — intervention group
Group type: EXPERIMENTAL
Intervention: Education sessions alone
Number of subjects: 442
Study 19529055 — intervention group
Group type: COMPARATOR
Intervention: No education sessions (control)
Number of subjects: 442
Study 17251278 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 12
Study 17251278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15789979 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate 360 degrees toothbrush
Number of subjects: 16
Study 15789979 — intervention group
Group type: COMPARATOR
Intervention: Oral‐B Indicator toothbrush
Number of subjects: 16
Study 15789979 — intervention group
Group type: COMPARATOR
Intervention: Crest SpinBrush PRO toothbrush
Number of subjects: 16
Study 15789979 — intervention group
Group type: COMPARATOR
Intervention: Oral‐B CrossAction toothbrush
Number of subjects: 16
Study 11197284 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged <60 years
Number of subjects: 41
Study 11197284 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged >=60 years
Number of subjects: 41
Study 11197284 — intervention group
Group type: COMPARATOR
Intervention: Control subjects aged <60 years
Number of subjects: 41
Study 11197284 — intervention group
Group type: COMPARATOR
Intervention: Control subjects aged >=60 years
Number of subjects: 41
Study 11197284 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of pharynx peak pressure
Number of subjects: 41
Study 9266953 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosylated G-CSF (5 microg/kg/d)
Number of subjects: 20
Study 9266953 — intervention group
Group type: COMPARATOR
Intervention: Non-glycosylated G-CSF
Number of subjects: 20
Study 8345034 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 20 267 (0.02 mg to 30 mg)
Number of subjects: 18
Study 8345034 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 20 267 (0.02 mg)
Number of subjects: 18
Study 8345034 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 20 267 (30 mg)
Number of subjects: 18